Mutations of key driver genes in gastric cancer metastasis risk: a systematic review and meta-analysis

Jin Wang(First Hospital of China Medical University), Zhi Li(Central Hospital Affiliated to Shenyang Medical College), Xiujuan Qu(First Hospital of China Medical University), Bowen Yang(Guangzhou University of Chinese Medicine), Jiawen Xiao(Shenyang Fifth People Hospital), Yunpeng Liu(Shenyang Institute of Automation), Ruichuan Shi(Ministry of Education of the People's Republic of China), Xinye Shao(First Hospital of China Medical University), Yang Liu(Shanxi Medical University)
Expert Review of Molecular Diagnostics
July 1, 2021
10.1080/14737159.2021.1946394
Cited by 9

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|The Lancet Oncology|2015|412